Effect of Exenatide on Abdominal Fat Distribution in Patients with Type 2 Diabetes Pretreated with Metformin

Study identifier:H8O-CA-GWCE

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

Effect of Exenatide on Abdominal Fat Distribution in Patients with Type 2 Diabetes Pretreated with Metformin

Medical condition

Diabetes Mellitus

Phase

Phase 2

Healthy volunteers

No

Study drug

placebo, exenatide

Sex

All

Actual Enrollment

80

Study type

Interventional

Age

18 Years - 85 Years

Date

Study Start Date: 01 Aug 2008
Primary Completion Date: 01 Jan 2012
Study Completion Date: 01 Jan 2012

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria